Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2008-007460-42 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-4367 in patients with cancer
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 | Experimental |
| |
| Arm 2 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BAY86-4367 | Drug | Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT |
|
| Measure | Description | Time Frame |
|---|---|---|
| Visual assessment of lesions | Day of study drug administration |
| Measure | Description | Time Frame |
|---|---|---|
| Quantitative analysis of BAY86-4367 uptake into lesions (Standardized Uptake Values = SUVs) | Day of study drug administration | |
| Electrocardiogram (ECG) | At least 3 times within 8 days after treatment |
Not provided
Inclusion Criteria:
Healthy volunteers:
Cancer patients:
Exclusion Criteria:
Exclusion criteria for all healthy volunteers and patients:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| München | Bavaria | 81675 | Germany | |||
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| BAY86-4367 | Drug | Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood |
|
| Blood pressure | At least 3 times within 8 days after treatment |
| Serum protein | At least 3 times within 8 days after treatment |
| Serum creatinine | At least 3 times within 8 days after treatment |
| Serum GOT (Glutamat-Oxalacetat-Transaminase) | At least 3 times within 8 days after treatment |
| Adverse events collection | At least 3 times within 8 days after treatment |
| Zurich |
| Canton of Zurich |
| 8091 |
| Switzerland |
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C556307 | BAY 86-4367 |
Not provided
Not provided
Not provided